CompanyABCLNasdaqVancouver, A1

AbCellera Biologics Inc.

AbCellera is a clinical-stage biotechnology company developing antibody-based medicines for endocrinology, women's health, immunology, and oncology.

SEC EDGAR ClinicalTrials.gov abcellera.com

10-KAug 28Latest SEC filing, period to Jun 30

Aug 13Latest story

August 2026

AbCellera completes pricing of $200 million offering, files final prospectus supplement

Aug 13FinancingAbCellera Biologics Inc.

AbCellera reports positive Phase 2 results for menopause drug ABCL635

Aug 10Clinical readoutAbCellera Biologics Inc.

July 2026

AbCellera to lead T-cell engager discovery for Vertex under new autoimmune disease pact

Jul 29PartnershipAbCellera Biologics Inc.

AbCellera appoints Lynn Seely to board of directors

Jul 6PeopleAbCellera Biologics Inc.